血清抗核抗体的存在并不影响非酒精性脂肪性肝病的长期预后。
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease.
机构信息
Department of Medical Sciences, Division of Gastroenterology and Hepatology, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
The Newcastle Liver Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
出版信息
Am J Gastroenterol. 2020 Aug;115(8):1289-1292. doi: 10.14309/ajg.0000000000000676.
INTRODUCTION
We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD).
METHODS
ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months.
RESULTS
Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative.
DISCUSSION
Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.
简介
我们研究了抗核抗体 (ANA) 对非酒精性脂肪性肝病 (NAFLD) 患者临床结局和生存的纵向影响。
方法
在 923 例经活检证实的 NAFLD 患者中，有 16.9% 发现了 ANA，但在平均 106±50 个月的随访中，没有一例患者存在组织学自身免疫性肝炎 (AIH) 或发生 AIH。
结果
尽管 ANA 阳性病例在基线时更易发生非酒精性脂肪性肝炎，但肝脏相关事件、肝细胞癌、心血管事件、肝外恶性肿瘤和总体生存率与 ANA 阴性病例相似。
讨论
一旦排除 AIH，ANA 阳性的 NAFLD 患者的长期结局和生存不受影响。
Zotero 插件